TrkA expression is associated with an elevated level of apoptosis in classic medulloblastomas

Takashi Ohta1, Takao Watanabe, Yoichi Katayama

  • 1Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.

Insights

Pediatric medulloblastoma prognosis is linked to clinical factors, not biological markers. The NGF/TrkA pathway

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Molecular Pathology

Background:

  • Medulloblastomas are the most common pediatric central nervous system malignancies.
  • Current treatments offer a dismal prognosis for affected children.
  • Understanding biological markers is crucial for improving outcomes.

Purpose of the Study:

  • To investigate the roles of cellular differentiation, proliferation, and apoptosis in pediatric medulloblastomas.
  • To assess the prognostic value of specific biological markers in medulloblastoma patients.
  • To explore potential novel therapeutic targets within signaling pathways.

Main Methods:

  • Immunohistochemistry was used to evaluate glial fibrillary acidic protein, S-100, synaptophysin, TrkA, and TrkC expression.
  • Proliferation index was assessed using MIB-1 staining.
  • Apoptotic index was determined via terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNL) assay.

Main Results:

  • TrkA expression correlated positively with MIB-1 (proliferation) and apoptotic indices.
  • No evaluated immunohistochemical markers predicted prognosis.
  • Tumor stage and extent of surgery were the primary predictors of survival.

Conclusions:

  • Clinical factors, not biological markers, are key prognostic indicators in this cohort.
  • The association between apoptosis and TrkA suggests the NGF/TrkA pathway as a potential therapeutic target.
  • Further research with larger sample sizes is needed to fully elucidate the role of biological variables.

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...